This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. DNTH, PHAT, GYRE, NRIX, MNMD, FTRE, DAWN, IMTX, DNA, and ABUSShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), Gyre Therapeutics (GYRE), Nurix Therapeutics (NRIX), Mind Medicine (MindMed) (MNMD), Fortrea (FTRE), Day One Biopharmaceuticals (DAWN), Immatics (IMTX), Ginkgo Bioworks (DNA), and Arbutus Biopharma (ABUS). These companies are all part of the "med - biomed/gene" industry. Elicio Therapeutics vs. Its Competitors Dianthus Therapeutics Phathom Pharmaceuticals Gyre Therapeutics Nurix Therapeutics Mind Medicine (MindMed) Fortrea Day One Biopharmaceuticals Immatics Ginkgo Bioworks Arbutus Biopharma Elicio Therapeutics (NASDAQ:ELTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Is ELTX or DNTH more profitable? Elicio Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Elicio Therapeutics' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elicio TherapeuticsN/A N/A -175.83% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Does the media prefer ELTX or DNTH? In the previous week, Dianthus Therapeutics had 7 more articles in the media than Elicio Therapeutics. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 1 mentions for Elicio Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.37 beat Elicio Therapeutics' score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Elicio Therapeutics Neutral Dianthus Therapeutics Neutral Which has preferable valuation & earnings, ELTX or DNTH? Elicio Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElicio Therapeutics$2.30M73.46-$51.90M-$6.95-1.49Dianthus Therapeutics$6.24M121.88-$84.97M-$3.25-7.27 Do insiders and institutionals have more ownership in ELTX or DNTH? 35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, ELTX or DNTH? Elicio Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Do analysts rate ELTX or DNTH? Elicio Therapeutics currently has a consensus target price of $13.00, indicating a potential upside of 25.73%. Dianthus Therapeutics has a consensus target price of $54.00, indicating a potential upside of 128.56%. Given Dianthus Therapeutics' higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDianthus Therapeutics beats Elicio Therapeutics on 10 of the 15 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.96M$3.07B$5.75B$9.74BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-2.6221.0631.3826.41Price / Sales73.46353.19428.94154.89Price / CashN/A44.7137.7559.42Price / Book94.008.0410.446.58Net Income-$51.90M-$53.98M$3.27B$265.92M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.7218 of 5 stars$10.34-0.4%$13.00+25.7%+165.5%$168.96M$2.30M-2.62N/ADNTHDianthus Therapeutics1.1789 of 5 stars$23.28+2.6%$53.00+127.7%-12.6%$749.06M$6.24M-7.1680PHATPhathom Pharmaceuticals2.6315 of 5 stars$10.53+1.4%$17.50+66.2%-23.8%$747.04M$114.04M-2.23110GYREGyre Therapeutics1.2556 of 5 stars$7.65+1.5%N/A-37.2%$736.29M$105.76M765.2740News CoverageAnalyst ForecastAnalyst RevisionNRIXNurix Therapeutics2.7882 of 5 stars$9.54-3.0%$28.87+202.5%-62.5%$728.94M$88.38M-3.65300News CoveragePositive NewsAnalyst UpgradeMNMDMind Medicine (MindMed)2.6824 of 5 stars$9.48+0.9%$24.71+160.8%+66.8%$721.16MN/A-6.1940Positive NewsFTREFortrea3.011 of 5 stars$7.71-2.3%$12.22+58.6%-57.4%$698.71M$2.70B-0.6815,500Positive NewsDAWNDay One Biopharmaceuticals2.5888 of 5 stars$6.82-0.1%$25.29+271.0%-45.9%$698.07M$187.64M-7.1760IMTXImmatics2.4135 of 5 stars$5.590.0%$14.67+162.4%-51.9%$677.16M$130.13M-8.57260DNAGinkgo Bioworks1.0572 of 5 stars$11.42-4.4%$8.50-25.6%+71.6%$674.64M$230.82M-1.94640ABUSArbutus Biopharma2.7202 of 5 stars$3.48-0.4%$5.50+58.3%-4.7%$666.16M$6.17M-11.9890Positive News Related Companies and Tools Related Companies DNTH Competitors PHAT Competitors GYRE Competitors NRIX Competitors MNMD Competitors FTRE Competitors DAWN Competitors IMTX Competitors DNA Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access